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OBJECTIVES: The current VLA disability questionnaire (L-VLA), which provides an 
assessment of disability in a broad range of life activities, queries difﬁculty in 33 
activities, with 4 follow-up questions for each activity regarding the need for accom-
modations (ACCs). Our objective was to create a short version of the questionnaire 
incorporating the use of ACCs, for rheumatoid arthritis (RA). METHODS: Data from 
2 years’ administration of the L-VLA in a longitudinal cohort of individuals with RA 
were used (n = 449,421). Analyses were ﬁrst conducted with Year 1 data and then 
validated with Year 2 data. Item response analyses were performed. Items were deleted 
based on misﬁt, logit values that duplicated information provided by other items 
providing information at similar logit values, and substantive considerations. Psycho-
metric properties of the short version (S-VLA) and L-VLA were compared. RESULTS: 
Partial credit and rating scale models were both tested; the partial credit model had 
fewer item and step misﬁts (G2 likelihood ratio = 623.881, p < 0.0001). The scoring 
range was expanded to 0–5 to account for use of ACCs. Deletions were progressive, 
resulting in a 21-item version, a 14-item version, and 4 12-item versions. A 14-activity 
version of the VLA questionnaire, with 1 follow-up question for each regarding ACCs, 
was selected. The S-VLA had 0 misﬁtting steps; 2 items had potential misﬁt but were 
retained for both substantive reasons and to provide logit spread. Correlation between 
L-VLA and S-VLA scores was 0.97; correlations of the L-VLA and S-VLA with other 
measures of functioning and RA impact were similar. Analyses were conﬁrmed in Year 
2 data. CONCLUSIONS: The S-VLA appears to be reliable and valid. The S-VLA 
may be more sensitive to change than other measures of functioning such as the HAQ 
and may appear more relevant to individuals with RA.
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OBJECTIVES: To observe, under actual conditions of use, the pain effect obtained, 
in the context of management of knee osteoarthritis, combining a prescription of 
Avian ACS between 2 courses of treatment of 3 injections of hyaluronic acid spaced 
out by a maximum of 12 months. METHODS: Pragmatic, longitudinal and prospec-
tive follow-up carried out by rheumatologists in the context of their daily professional 
activities; the investigator does not change the prescription or management habits. 
RESULTS: A total of 201 patients are treated with hyaluronic acid and Avian ACS. 
The average age is 65.30 years (± 7.10). Average pain during activities of daily living 
(ADL) was measured by means of a visual analogue scale (VAS). It is 52.02 ± 20.53 
at inclusion. At 6 months, this same average pain measured under the same conditions 
is 33.58 ± 25.21. A third measurement at 12 months situates it at 30.44 ± 22.86. Pain 
during ADL is signiﬁcantly reduced between inclusion and month 6 (p < 0.0001) and 
between inclusion and month 12 (p < 0.0001). Accordingly, the reduction obtained 
in 12 months is 41%. With regard to pain measured at rest, it was also measured at 
inclusion, at 6 and 12 months, by means of VAS. There is a signiﬁcant reduction in 
pain at rest between inclusion and 6 months (p = 0.0052) and the reduction between 
inclusion and month 12 is also signiﬁcant (p = 0.0005). At inclusion, 6 and 12 months, 
the average pain observed is 29.86 ± 21.16, 20.95 ± 23.13 and 17.33 ± 6.97, respec-
tively. CONCLUSIONS: Our study, which assesses the effect on pain obtained in the 
context of management of subjects with knee osteoarthritis, combining a prescription 
of Avian ACS between 2 courses of treatment of 3 injections of hyaluronic acid, 
showed a reduction in pain during ADL. This reduction in pain, which is signiﬁcant 
at 6 months, then perpetuated at 12 months, shows the relevance of the treatment 
protocol used by the doctors.
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OBJECTIVES: This study aimed to investigate the differences in the levels of peri-
operative pain and peri-operative health-related quality of life (HRQOL) in the 
patients underwent orthopedic surgery. METHODS: This study is multi-center and 
cross sectional study based on patients survey. Total 687 patients in 36 tertiary hos-
pitals who are supposed to be performed orthopedic surgery (arthroplasty and spinal 
fusion) were interviewed. Clinical, surgery proﬁle, and quality of life data were col-
lected. Subjects completed a face-to-face interview with trained interviewer to assess 
their health status, patients satisfaction, pain scale for pain management. we obtained 
the quality of data through 3 interviews; before surgery day, post op 14 days f/w 
(POD14) and post op 3 months f/w. we enrolled the patients during maximum 4 
months (July∼ December 2009) RESULTS: Generally. the Quality of life of patients 
before surgery were lower than those of patients in POD 14. In average, utility weight 
of before surgery and POD 14 is 0.31 and 0.57. Patients who have been heard about 
the surgery pain from hospital staffs expected pain worse than those of who haven’t. 
so VAS pain scores have signiﬁcant gap between expected pain and POD 1 (patients 
who have been heard about the surgery pain : 72.68, POD1: 65.63/patients who 
haven’t been :57.89, POD1: 67.25) There were signiﬁcantly differences for using pre-
emptive analgesics and pain management. the patients who were used for pre-emptive 
analgesics show the improvements compared to those who weren’t used. CONCLU-
SIONS: There is few study of Quality of life for real patients in korea. so it is meaning-
ful to draw the utility weight of orthopedic surgery for patients. The ﬁndings suggest 
that utility weight for arthritis is lower compared to the results from national heatlh 
survey aiming at residents in korea (arthritis: 0.7621 from 2005 KNHANES).
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OBJECTIVES: Ustekinumab(UST) has been shown to improve psoriasis(PsO) and 
health-related quality of life (HRQoL) in patients(pts) with moderate-to-severe PsO*. 
This analysis examines the effects of UST on overall skin response and the impact on 
HRQoL in a subset of PsO pts with psoriatic arthritis(PsA). METHODS: In PHOENIX 
1 and 2, pts with moderate-to-severe PsO(n = 1996) were randomized to UST45mg 
or 90 mg at wks 0, 4, and q12 wk thereafter, or placebo(PBO) at wks 0 and 4 with 
crossover to UST at wk12. PsA was identiﬁed in pts by medical history. PsO severity 
was assessed using the Psoriasis Area and Severity Index(PASI) and HRQoL with the 
Dermatology Life Quality Index (DLQI). RESULTS: At baseline, 563(28.2%) pts had 
PsA. The mean PASI was 20.7(SD = 8.4) and mean DLQI was 12.6(SD = 7.2) indicat-
ing signiﬁcant poor HRQoL. At wk12, UST-treated pts had a signiﬁcantly greater 
percent improvement in mean PASI score than PBO-treated pts(45 mg: 73.7%, 90 mg: 
75.3%, PBO: 2.4%; p < 0.001). A signiﬁcantly greater portion of UST-treated pts 
achieved PASI75 compared to PBO-treated pts(45 mg: 63.0%, 90 mg: 61.5%, PBO: 
3.6%; p < 0.001). UST-treated pts had a signiﬁcantly greater decrease (improvement) 
in DLQI score at wk12 than PBO-treated pts(45 mg: −9.2 [SD = 7.1], 90 mg: −9.7[SD 
= 6.6], PBO: −0.01[SD = 5.0]; p < 0.001). At wk12, 70.2% in the UST 45 mg group 
and 75.0% in the UST 90 mg group respectively, experienced ≥5 point improvement 
in DLQI compared to 15.6 % for the PBO group (p < 0.001). UST-treated pts (50.0% 
and 57.1% in the 45 mg and 90 mg groups, respectively) had a DLQI score of 0 or 
1, indicating no impact of the disease or treatment on HRQoL compared with 1.0% 
of PBO-treated pts (p < 0.001). CONCLUSIONS: UST improved overall skin response 
and HRQoL in a subset of moderate-to-severe PsO pts with PsA. This ﬁnding will be 
further evaluated in various ongoing prospective Phase 3 studies.*Lebwohl M, Papp 
K, Han C, et al. Br J Dermatol 2009;162(1):pg 137–146.
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AND EQ-5D METHODS
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OBJECTIVES: To explore the adaption of quality-of-life (QoL) measurements and 
establish appropriate utility measure for Taiwanese rheumatoid arthritis (RA) patients, 
this study aims to apply both direct and indirect QoL measures and assess potential 
inﬂuencing factors. METHODS: A cross-sectional study was conducted at a medical 
center in Southern Taiwan from June to November 2009. Adult RA outpatients were 
invited for interviews, while health-related quality of life was measured by time-trade-
off (TTO), Euroqol (EQ-5D) questionnaire and visual analogue scale (EQ-5D VAS). 
The EQ-5D assessment was transformed into EQ-5D index using Japanese preference 
weight. Patients’ details on demography, disease activity score 28 (DAS28) and current 
medicine were also collected. Multivariate analysis was used to evaluate relationship 
between patients’ details and utility values as well as the ﬁve dimensions of EQ-5D. 
RESULTS: Seventy-nine adult RA outpatients were successfully interviewed (86% 
women, mean age 55.23 ± 11.30 years, and mean RA history: 9.5 ± 4.98 years). Mean 
utility value measured by EQ-5D VAS, EQ-5D index and TTO were 63.66 ± 19.85, 
0.71 ± 0.18 and 0.58 ± 0.32, irrespectively. Patients with higher disease activity 
reported lower utility and more difﬁculties in the EQ-5D’s ﬁve dimensions. Stratifying 
by medications, patients using biological agents (N = 32) have higher disease activity 
(higher DAS28) than others (N = 47), but there is no signiﬁcant difference in utility 
scores. After adjusting demography and EQ-5D dimensions, disease activity is associ-
ated with all utility measures, but there are more factors (marriage, selfcare problems, 
depression and weekly dose of methotrexate) inﬂuencing the TTO score. CONCLU-
SIONS: For Taiwanese RA patients, EQ-5D index is only and highly associated with 
the disease activity, and therefore this instrument may be an appropriate to assess 
local RA patients’ QoL. However, since there is no Taiwanese EQ-5D value sets for 
deriving EQ-5D index, it is necessary to develop the Taiwanese population-based 
preference weight for EQ-5D in the future.
